Adastra Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Adastra Pharmaceuticals, Inc.
Private Company Edition: In addition to Adiso, Creyon recently launched with $40m and TRexBio extended its series A by $26m to $85m total. Also, Kurma Partners raised the first €160m of a planned €250m fund to back companies transitioning from R&D to commercial operations.
The most desirable form of vascular access for most hemodialysis patients is an arteriovenous fistula (AVF). Flow Forward believes it can expand the AVF prevalence rate to 90% with its Arteriovenous Fistula Eligibility (AFE) System, a temporary external blood pump that rapidly dilates peripheral veins prior to AVF surgery.
China-listed Jinghua Pharmaceutical has tapped into developing biologic drug through investment and licensing agreement with US-based Kadmon, shifting from a traditional Chinese medicine maker to mAbs developer. The company has seen increasing competition and revenue drops in Chinese traditional medicine industry.
First Minimally Invasive Vascular Access Technology Has Potential to Revolutionize Growing Hemodialysis Market
With a projected worldwide market of over three million hemodialysis patients by 2020, TVA Medical Inc. sees a potential $1 billion+ annual market opportunity with everlinQ, a minimally invasive, catheter-based system that allows physicians to use an endovascular approach to create an arteriovenous fistula (AVF) for vascular access in chronic kidney patients who require ongoing hemodialysis.
- Specialty Pharmaceuticals
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
- Tragara Pharmaceuticals, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.